12 results on '"Pandya, Shree"'
Search Results
2. Cardiovascular health supervision for Duchenne Muscular Dystrophy; data from the MD STARnet
- Author
-
Wittlieb-Weber, Carol A., Pantea, Cristian, Krikov, Sergey, Westfield, Christina, Fox, Deborah J., Pandya, Shree, Bounsanga, Jerry, Johnson, Nicholas E., Butterfield, Russell J., Venkatesh, Y. Swamy, and Ciafaloni, Emma
- Published
- 2018
- Full Text
- View/download PDF
3. Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy
- Author
-
Statland, Jeffrey M., McDermott, Michael P., Heatwole, Chad, Martens, William B., Pandya, Shree, van der Kooi, E.L., Kissel, John T., Wagner, Kathryn R., and Tawil, Rabi
- Published
- 2013
- Full Text
- View/download PDF
4. PII: S0960-8966(17)30577-1
- Author
-
Bartels, Bart, Civitello, Matthew, Coratti, Giorgia, Young, Sally Dunaway, Duong, Tina, Estilow, Timothy, Gee, Richard, Glanzman, Allan M., Kitsuwa-Lowe, Janis, Main, Marion, Mayhew, Anna, Mazzone, Elena, Mirek, Elizabeth, Montes, Jacqueline, Lofra, Robert Muni, Pandya, Shree, Pasternak, Amy, Ramsey, Danielle, Salazar, Rachel, Turner, Jenna, and Wells, Julie
- Published
- 2017
- Full Text
- View/download PDF
5. Delayed Diagnosis in Duchenne Muscular Dystrophy: Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).
- Author
-
Ciafaloni, Emma, Fox, Deborah J., Pandya, Shree, Westfield, Christina P., Puzhankara, Soman, Romitti, Paul A., Mathews, Katherine D., Miller, Timothy M., Matthews, Dennis J., Miller, Lisa A., Cunniff, Christopher, Druschel, Charlotte M., and Moxley, Richard T.
- Abstract
Objective: To identify key factors for the delay in diagnosis of Duchenne muscular dystrophy (DMD) without known family history. Study design: The cohort comes from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet), a multistate, multiple-source, population-based surveillance system that identifies and gathers information on all cases of Duchenne and Becker muscular dystrophy born since 1982. We analyzed medical records of 453 Duchenne and Becker muscular dystrophy boys to document the time course and steps taken to reach a definitive diagnosis. Results: Among 156 boys without known family history of DMD prior to birth, first signs or symptoms were noted at a mean age of 2.5 years. Concerns resulted in primary care provider evaluation of the child at a mean age of 3.6 years. Mean age at time of initial creatine kinase was 4.7 years. Mean age at definitive diagnosis of DMD was 4.9 years. Conclusions: There is a delay of about 2.5 years between onset of DMD symptoms and the time of definitive diagnosis, unchanged over the previous 2 decades. This delay results in lost opportunities for timely genetic counseling and initiation of corticosteroid treatment. We recommend checking creatine kinase early in the evaluation of boys with unexplained developmental delay. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
6. Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.
- Author
-
Lamb, Molly M., West, Nancy A., Ouyang, Lijing, Yang, Michele, Weitzenkamp, David, James, Katherine, Ciafaloni, Emma, Pandya, Shree, DiGuiseppi, Carolyn, and Muscular Dystrophy Surveillance, Research, and Tracking Network (MD STARnet)
- Abstract
Objectives: To evaluate growth patterns of ambulatory males with Duchenne muscular dystrophy (DMD) treated with corticosteroids compared with ambulatory, steroid-naïve males with DMD and age-matched unaffected general-population males and to test associations between growth and steroid treatment patterns among treated males.Study Design: Using data from the Muscular Dystrophy Surveillance, Tracking, and Research Network, we identified a total of 1768 height, 2246 weight, and 1755 body mass index (BMI) measurements between age 2 and 12 years for 324 ambulatory males who were treated with corticosteroids for at least 6 months. Growth curve comparisons and linear mixed-effects modeling, adjusted for race/ethnicity and birth year, were used to evaluate growth and steroid treatment patterns (age at initiation, dosing interval, duration, cumulative dose).Results: Growth curves for ambulatory males treated with corticosteroids showed significantly shorter stature, heavier weight, and greater BMI compared with ambulatory, steroid-naïve males with DMD and general-population US males. Adjusted linear mixed-effects models for ambulatory males treated with corticosteroids showed that earlier initiation, daily dosing, longer duration, and greater dosages predicted shorter stature with prednisone. Longer duration and greater dosages predicted shorter stature for deflazacort. Daily prednisone dosing predicted lighter weight, but longer duration, and greater dosages predicted heavier weight. Early initiation, less than daily dosing, longer duration, and greater doses predicted greater BMIs. Deflazacort predicted shorter stature, but lighter weight, compared with prednisone.Conclusion: Prolonged steroid use is significantly associated with short stature and heavier weight. Growth alterations associated with steroid treatment should be considered when making treatment decisions for males with DMD. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
7. Oral Corticosteroids and Onset of Cardiomyopathy in Duchenne Muscular Dystrophy.
- Author
-
Barber, Brent J., Andrews, Jennifer G., Lu, Zhenqiang, West, Nancy A., Meaney, F. John, Price, Elinora T., Gray, Ashley, Sheehan, Daniel W., Pandya, Shree, Yang, Michele, and Cunniff, Christopher
- Abstract
Objective: To estimate the age when cardiomyopathy develops in boys with Duchenne muscular dystrophy (DMD) and to analyze the effect of corticosteroid treatment on the age of cardiomyopathy onset. Study design: We identified a population-based sample of 462 boys with DMD, born between 1982 and 2005, in 5 surveillance sites in the US. Echocardiographic and corticosteroid treatment data were collected. Cardiomyopathy was defined by a reduced fractional shortening (<28%) or ejection fraction (<55%). The age of cardiomyopathy onset was determined. Survival analysis was performed to determine the effects of corticosteroid treatment on cardiomyopathy onset. Results: The mean (SD) age of cardiomyopathy onset was 14.3 (4.2) years for the entire population and 15.2 (3.4) years in corticosteroid-treated vs 13.1 (4.8) in non-treated boys. Survival analysis described a significant delay of cardiomyopathy onset for boys treated with corticosteroids (P < .02). By 14.3 years of age, 63% of non-treated boys had developed cardiomyopathy vs only 36% of those treated. Among boys treated with corticosteroids, there is a significant positive effect of duration of corticosteroid treatment on cardiomyopathy onset (P < .0001). For every year of corticosteroid treatment, the probability of developing cardiomyopathy decreased by 4%. Conclusions: Oral corticosteroid treatment was associated with delayed cardiomyopathy onset. The duration of corticosteroid treatment also correlated positively with delayed cardiomyopathy onset. Our analysis suggests that a boy with DMD treated for 5 years with corticosteroids might experience a 20% decrease in the likelihood of developing cardiomyopathy compared with untreated boys. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
8. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.
- Author
-
Birnkrant, David J, Bushby, Katharine, Bann, Carla M, Apkon, Susan D, Blackwell, Angela, Brumbaugh, David, Case, Laura E, Clemens, Paula R, Hadjiyannakis, Stasia, Pandya, Shree, Street, Natalie, Tomezsko, Jean, Wagner, Kathryn R, Ward, Leanne M, Weber, David R, and DMD Care Considerations Working Group
- Subjects
- *
DIAGNOSIS of Duchenne muscular dystrophy , *NEUROMUSCULAR diseases , *MEDICAL rehabilitation , *GASTROINTESTINAL disease treatment , *NUTRITION , *TREATMENT of Duchenne muscular dystrophy , *DIET therapy , *DUCHENNE muscular dystrophy , *GASTROINTESTINAL system , *MYONEURAL junction , *RESEARCH funding , *DISEASE management , *ENDOCRINE system - Abstract
Since the publication of the Duchenne muscular dystrophy (DMD) care considerations in 2010, multidisciplinary care of this severe, progressive neuromuscular disease has evolved. In conjunction with improved patient survival, a shift to more anticipatory diagnostic and therapeutic strategies has occurred, with a renewed focus on patient quality of life. In 2014, a steering committee of experts from a wide range of disciplines was established to update the 2010 DMD care considerations, with the goal of improving patient care. The new care considerations aim to address the needs of patients with prolonged survival, to provide guidance on advances in assessments and interventions, and to consider the implications of emerging genetic and molecular therapies for DMD. The committee identified 11 topics to be included in the update, eight of which were addressed in the original care considerations. The three new topics are primary care and emergency management, endocrine management, and transitions of care across the lifespan. In part 1 of this three-part update, we present care considerations for diagnosis of DMD and neuromuscular, rehabilitation, endocrine (growth, puberty, and adrenal insufficiency), and gastrointestinal (including nutrition and dysphagia) management. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
- Author
-
Bushby, Katharine, Finkel, Richard, Birnkrant, David J, Case, Laura E, Clemens, Paula R, Cripe, Linda, Kaul, Ajay, Kinnett, Kathi, McDonald, Craig, Pandya, Shree, Poysky, James, Shapiro, Frederic, Tomezsko, Jean, and Constantin, Carolyn
- Subjects
- *
DIAGNOSIS of Duchenne muscular dystrophy , *MUSCULAR dystrophy treatment , *CARDIOVASCULAR services in hospitals , *HOSPITAL gastroenterology services , *MEDICAL rehabilitation , *LITERATURE reviews - Abstract
Summary: Optimum management of Duchenne muscular dystrophy (DMD) requires a multidisciplinary approach that focuses on anticipatory and preventive measures as well as active interventions to address the primary and secondary aspects of the disorder. Implementing comprehensive management strategies can favourably alter the natural history of the disease and improve function, quality of life, and longevity. Standardised care can also facilitate planning for multicentre trials and help with the identification of areas in which care can be improved. Here, we present a comprehensive set of DMD care recommendations for management of rehabilitation, orthopaedic, respiratory, cardiovascular, gastroenterology/nutrition, and pain issues, as well as general surgical and emergency-room precautions. Together with part 1 of this Review, which focuses on diagnosis, pharmacological treatment, and psychosocial care, these recommendations allow diagnosis and management to occur in a coordinated multidisciplinary fashion. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
10. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
- Author
-
Bushby, Katharine, Finkel, Richard, Birnkrant, David J, Case, Laura E, Clemens, Paula R, Cripe, Linda, Kaul, Ajay, Kinnett, Kathi, McDonald, Craig, Pandya, Shree, Poysky, James, Shapiro, Frederic, Tomezsko, Jean, Constantin, Carolyn, and DMD Care Considerations Working Group
- Subjects
- *
DIAGNOSIS of Duchenne muscular dystrophy , *PROGRESSIVE patient care , *STRESS management , *PHARMACOLOGY , *MEDICAL rehabilitation , *PSYCHOSOCIAL factors - Abstract
Summary: Duchenne muscular dystrophy (DMD) is a severe, progressive disease that affects 1 in 3600–6000 live male births. Although guidelines are available for various aspects of DMD, comprehensive clinical care recommendations do not exist. The US Centers for Disease Control and Prevention selected 84 clinicians to develop care recommendations using the RAND Corporation–University of California Los Angeles Appropriateness Method. The DMD Care Considerations Working Group evaluated assessments and interventions used in the management of diagnostics, gastroenterology and nutrition, rehabilitation, and neuromuscular, psychosocial, cardiovascular, respiratory, orthopaedic, and surgical aspects of DMD. These recommendations, presented in two parts, are intended for the wide range of practitioners who care for individuals with DMD. They provide a framework for recognising the multisystem primary manifestations and secondary complications of DMD and for providing coordinated multidisciplinary care. In part 1 of this Review, we describe the methods used to generate the recommendations, and the overall perspective on care, pharmacological treatment, and psychosocial management. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
11. PROGRESSION OF LEFT VENTRICULAR DYSFUNCTION IN CHILDHOOD-ONSET DUCHENNE AND BECKER MUSCULAR DYSTROPHIES.
- Author
-
Ridall, Leslie, Gralla, Jane, Mourani, Peter M., Czaja, Angela, Yang, Michele, Cunniff, Christopher, Donnelly, Jennifer A., Ciafaloni, Emma, Oleszek, Joyce, Pandya, Shree, Price, Elinora, and Auerbach, Scott
- Published
- 2014
- Full Text
- View/download PDF
12. Kate Bushby
- Author
-
Bushby, Katharine, Finkel, Richard, Birnkrant, David J, Case, Laura E, Clemens, Paula R, Cripe, Linda, Kaul, Ajay, Kinnett, Kathi, McDonald, Craig, Pandya, Shree, Poysky, James, Shapiro, Frederic, Tomezsko, Jean, Constantin, Carolyn, and DMD Care Considerations Working Group
- Subjects
- *
DIAGNOSIS of Duchenne muscular dystrophy , *TREATMENT of Duchenne muscular dystrophy , *DIFFERENTIAL diagnosis , *DUCHENNE muscular dystrophy , *GLUCOCORTICOIDS ,THERAPEUTIC use of glucocorticoids - Abstract
Duchenne muscular dystrophy (DMD) is a severe, progressive disease that affects 1 in 3600-6000 live male births. Although guidelines are available for various aspects of DMD, comprehensive clinical care recommendations do not exist. The US Centers for Disease Control and Prevention selected 84 clinicians to develop care recommendations using the RAND Corporation-University of California Los Angeles Appropriateness Method. The DMD Care Considerations Working Group evaluated assessments and interventions used in the management of diagnostics, gastroenterology and nutrition, rehabilitation, and neuromuscular, psychosocial, cardiovascular, respiratory, orthopaedic, and surgical aspects of DMD. These recommendations, presented in two parts, are intended for the wide range of practitioners who care for individuals with DMD. They provide a framework for recognising the multisystem primary manifestations and secondary complications of DMD and for providing coordinated multidisciplinary care. In part 1 of this Review, we describe the methods used to generate the recommendations, and the overall perspective on care, pharmacological treatment, and psychosocial management. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.